GlassScriptPhysician profile
Eric M Drummer
NPI 1932191525
$9,398.95
in general payments reported to CMS, 2019-2025
41 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,537 · 2020: $885 · 2021: $1,624 · 2022: $963 · 2023: $989 · 2024: $1,919 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,390.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,390.72 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $1,012.89 | 2019-2025 | |
| Edwards Lifesciences Corporation | $892.94 | 2019-2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $714.41 | 2019-2025 | Mitraclip, Cardiomems, Perclose Prostyle |
| Medtronic, INC. | $675.24 | 2021-2025 | Symplicity G3, Micra, Azure Xt Dr Mri Surescan |
| Boston Scientific Corporation | $619.64 | 2023-2025 | Watchman Access System, Avvigo Guidance System, Watchman Flx |
| Biotronik INC. | $431.84 | 2019-2025 | Acticor 7 Vr-T Dx, Biomonitor, Amvia Edge |
| Amgen INC. | $408.60 | 2019-2025 | Repatha |
| Pfizer INC. | $188.34 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $180.64 | 2022-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $154.01 | 2019-2022 | |
| Medtronic Vascular, INC. | $127.86 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $118.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $117.84 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.05 | 2019-2024 | Camzyos |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $111.61 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.15 | 2019-2023 | Jardiance |
| Heartflow, INC. | $98.23 | 2025 | |
| Biosense Webster, INC. | $80.90 | 2019-2024 | Qdot Micro Catheter, Visitag Surpoint External Processing Unit |
| Esperion Therapeutics, INC. | $78.24 | 2020-2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $65.10 | 2020-2025 | Amvuttra |
| Penumbra, INC. | $63.94 | 2025 | Indigo System |
| Merck Sharp & Dohme LLC | $63.52 | 2021-2022 | |
| Atricure, INC. | $51.24 | 2024 | |
| Teleflex LLC | $47.69 | 2019-2020 | |
| Inari Medical, INC. | $45.96 | 2022 | |
| Irhythm Technologies, INC. | $44.95 | 2023-2024 | Zio Xt Patch |
| Philips North America LLC | $43.66 | 2024 | (Cm9) Amb Mon & Diag Und |
| Bayer Healthcare Pharmaceuticals INC. | $36.68 | 2025 | |
| Novo Nordisk INC | $36.52 | 2025 | Wegovy |
| Akcea Therapeutics, INC. | $36.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.12 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $35.36 | 2019 | |
| Amarin Pharma, INC. | $31.41 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $26.16 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $25.97 | 2023 | Inpefa |
| Elutia, INC. | $21.21 | 2019 | |
| Lilly USA, LLC | $18.29 | 2025 | Mounjaro, Zepbound |
| Kiniksa Pharmaceuticals, LTD. | $17.51 | 2021 | |
| United Therapeutics Corporation | $15.58 | 2019 | |
| Tactile Systems Technology INC | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Drummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.